Alpine | Jotup

Alpine Immune Sciences Reports First Quarter 2024 Financial Results

Retrieved on:

Donnerstag, Mai 9, 2024

Biotechnology, Pharmaceutical, Health, VRTX, ALPN, Investment, Research program, AbbVie, Research, Development, Alpine, Inflammation, Clinical trial, Vertex, Autoimmunity, Vertex Pharmaceuticals, Pharmaceutical industry

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024.

Key Points:

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024.
On April 10, 2024, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine announced that the companies had entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share in cash.
The transaction was unanimously approved by both the Vertex and Alpine Boards of Directors and is anticipated to close in the second quarter of 2024.
Cash Position and Runway: As of March 31, 2024, Alpine's cash and investments totaled $362.4 million compared to $368.2 million as of December 31, 2023.

Alpine Power Systems Upgrades to a Larger Facility in Houston, TX

Retrieved on:

Mittwoch, Mai 8, 2024

Alpine, Suite, Investment, Motive Power, Texas Triangle

HOUSTON, May 8, 2024 /PRNewswire/ -- Alpine Power Systems is thrilled to declare the successful relocation to a new, more sizeable facility in Houston, TX.

Key Points:

HOUSTON, May 8, 2024 /PRNewswire/ -- Alpine Power Systems is thrilled to declare the successful relocation to a new, more sizeable facility in Houston, TX.
This significant accomplishment coincides with the company's two-decade presence in Texas.
The decision to relocate from their previous facility was made to accommodate the expansion of their Motive Power, Telecom, and Critical Power divisions.
The new Alpine facility is situated at 2700 Greens Road, Building G, Suite 100, Houston, Texas 77032.

Alpine Banks of Colorado announces financial results for first quarter 2024

Retrieved on:

Donnerstag, Mai 2, 2024

Total, OTCQX, Bank, Risk-weighted asset, Alpine, Growth

GLENWOOD SPRINGS, Colo., May 02, 2024 (GLOBE NEWSWIRE) -- Alpine Banks of Colorado (OTCQX: ALPIB) (“Alpine” or the “Company”), the holding company for Alpine Bank (the “Bank”), today announced results (unaudited) for the quarter ended March 31, 2024.

Key Points:

GLENWOOD SPRINGS, Colo., May 02, 2024 (GLOBE NEWSWIRE) -- Alpine Banks of Colorado (OTCQX: ALPIB) (“Alpine” or the “Company”), the holding company for Alpine Bank (the “Bank”), today announced results (unaudited) for the quarter ended March 31, 2024.
Highlights in first quarter 2024 include:
Basic earnings per Class A common share decreased 3.9%, or $3.94, during first quarter 2024.
Net interest margin for first quarter 2024 was 2.81%, compared to 2.84% in fourth quarter 2023, and 3.52% in first quarter 2023.
Interest income increased $0.9 million in first quarter 2024 compared to fourth quarter 2023, primarily due to increases in yields on the loan portfolio, the securities portfolio, and balances due from banks.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INRD, AIRC, ELYM, ALPN

Retrieved on:

Montag, April 22, 2024

Sale, Advertising, Alpine, Therapy, Aimco, Fraud, Vertex Pharmaceuticals, Security (finance)

If you are an Inrad shareholder, click here to learn more about your rights and options .

Key Points:

If you are an Inrad shareholder, click here to learn more about your rights and options .
If you are an Apartment Income shareholder, click here to learn more about your rights and options .
Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ADTH, MODN, ALPN

Retrieved on:

Samstag, April 20, 2024

Alpine, Sale, Vista Equity Partners, Model N, Advertising, Fraud, Vertex Pharmaceuticals, Security (finance)

If you are an AdTheorent shareholder, click here to learn more about your rights and options .

Key Points:

If you are an AdTheorent shareholder, click here to learn more about your rights and options .
If you are a Model N shareholder, click here to learn more about your rights and options .
Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MGRC, ALPN, NXPL

Retrieved on:

Dienstag, April 16, 2024

Alpine, Sale, Advertising, Fraud, Vertex Pharmaceuticals, Security (finance)

If you are a McGrath shareholder, click here to learn more about your rights and options .

Key Points:

If you are a McGrath shareholder, click here to learn more about your rights and options .
Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MODN, ALPN, ELYM, JBT

Retrieved on:

Samstag, April 13, 2024

Alpine, Sale, Vista Equity Partners, JBT, Model N, JBT Corporation, Advertising, Fraud, Vertex Pharmaceuticals, Security (finance)

If you are a Model N shareholder, click here to learn more about your rights and options .

Key Points:

If you are a Model N shareholder, click here to learn more about your rights and options .
If you are a JBT shareholder, click here to learn more about your rights and options .
Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Alpine Bank announces changes to its Board of Directors

Retrieved on:

Donnerstag, April 11, 2024

Thought, Digital, Colorado River, Alicja Kornasiewicz, Karow, Alpine, Accounting

“We thank and honor John, Stan, Bruce, and Dave for their service to the bank and our communities,” said Glen Jammaron, president of Alpine Bank.

Key Points:

“We thank and honor John, Stan, Bruce, and Dave for their service to the bank and our communities,” said Glen Jammaron, president of Alpine Bank.
“The changes to the board support the vision of Alpine Bank as we continue to operate as a forward thinking, independent, community focused, Colorado bank,” said Jammaron.
Gardey joined Alpine Bank in 1989 and has served the bank in various finance, accounting, and audit roles.
Additional background on the outgoing board members:
John Cooper got his start at Alpine Bank in Snowmass Village in 1979, and he was appointed to the board of directors that same year.

Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy

Retrieved on:

Mittwoch, April 10, 2024

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today shared updated clinical data for povetacicept in IgA nephropathy (IgAN) which will be presented as a late breaking poster at the World Congress of Nephrology (WCN) April 13-16, 2024 in Buenos Aires, Argentina.

Key Points:

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today shared updated clinical data for povetacicept in IgA nephropathy (IgAN) which will be presented as a late breaking poster at the World Congress of Nephrology (WCN) April 13-16, 2024 in Buenos Aires, Argentina.
RUBY-3 is a multiple ascending dose, multi-cohort, open label, phase 1b/2a study of povetacicept in autoimmune glomerulonephritis, including IgA nephropathy, where povetacicept is administered subcutaneously (SC) once every four weeks.
As of March 01, 2024, 41 patients with IgAN had received povetacicept 80 or 240 mg subcutaneously every 4 weeks.
These data strongly support the inhibition of APRIL/BAFF pathways by povetacicept and its efficacy in the treatment of IgAN as well as the need for further clinical development.

Discover Unique, Only-in-Vail Moments this Summer

Retrieved on:

Mittwoch, April 24, 2024

VAIL, Colo., April 24, 2024 /PRNewswire/ -- This summer, discover unique only-in-Vail moments with new events, flights and more.

Key Points:

VAIL, Colo., April 24, 2024 /PRNewswire/ -- This summer, discover unique only-in-Vail moments with new events, flights and more.
Exciting news for travelers as Eagle County Regional Airport (EGE) doubles its summer flight routes beginning this June.
She will also have a display of images from her internationally acclaimed Red Road Project in the Town's Municipal Building throughout the summer.
New this summer, Solaris Plaza will offer brides and grooms the opportunity to host their wedding ceremony on the Solaris Lawn.